Clinical Study On The Efficacy Of Poria Cocos Oral Solution In Reducing Adverse Reactions To Platinum-containing Chemotherapy

Objective:To observe the adverse reactions of sputum polysaccharide oral solution in reducing the chemotherapy-related two drugs of NSCLC.Methods:A total of 52 patients who met the inclusion and exclusion criteria in the oncology department of the Affiliated Hospital of Traditional Chinese Medicine,Xinjiang Medical University from December2017 to January 2019 were enrolled.The randomized controlled trials were divided into experimental group(28 cases)and control group(24 cases)..The control group was given platinum-containing chemotherapy.The experimental group was combined with sputum polysaccharide oral solution on the basis of the control group.One chemotherapy cycle was performed for 21 days,and one chemotherapy cycle was for one chemotherapy cycle.Two chemotherapy cycles were observed.The two groups of patients were examined for complete blood cell analysis and biochemical indicators before the first and second chemotherapy cycles.The blood routine was checked about 7 days after the first and second cycles of chemotherapy,and the adverse drug reaction evaluation,clinical symptom score,and quality of life were also performed.score.The data were analyzed using SPSS22.0 statistical software.Results:(1)Comparison of myelosuppression: There was no significant difference in the overall incidence of myelosuppression between the two groups(P>0.05);(2)Comparison of digestive tract reactions: loss of appetite: the number of symptoms and the proportion of loss of appetite in the test group Lower than the control group,but after statistical analysis P>0.05,the statistical difference was not significant.Nausea and vomiting: The number of nausea and vomiting symptoms in the experimental group and the proportion were higher than the control group,while thenumber of nausea and vomiting symptoms in the experimental group was higher than that in the control group.After statistical analysis,P>0.05,the statistical difference was not significant;(4)Comparison of quality of life scores: The two groups of treatment methods did not improve the quality of life in terms of physical function,role function,emotional function,etc.,while in the fatigue symptoms and insomnia symptoms scores,the fatigue symptoms scores of the experimental group and the control group were better than those before treatment.Reduced,the difference between the two groups by the rank sum test P<0.05,indicating that the polysaccharide oral liquid has a clear advantage in improving the symptoms of fatigue.Conclusion: The polysaccharide polysaccharide oral liquid has no significant effect on reducing the incidence of bone marrow suppression after chemotherapy;it has no obvious improvement effect on the symptoms of appetite loss,nausea and vomiting in the digestive tract reaction;it can improve the clinical symptoms of patients after chemotherapy;quality of life: The polysaccharide oral liquid has no improvement in the quality of life in the fields of physical function,role function and emotional function;it has a significant advantage in improving the symptoms of fatigue and insomnia.